AHA Updates Emergency Department Guidelines for Acute Migraine Treatment

Migraine remains one of the most common neurological reasons for ED visits, yet many patients receive therapies that are either unsupported by evidence or associated with unnecessary risks. To address this, the guideline authors conducted a comprehensive systematic review and meta-analysis using the same rigorous methodology as the 2016 guideline, while expanding the scope to include nerve blocks and sphenopalatine ganglion (SPG) blocks. Major databases, including Medline, Embase, Cochrane, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform, were searched through February 10, 2025.

The review identified 26 new randomized controlled trials evaluating 20 injectable or procedural treatments for adults presenting to the ED with migraine. Study quality was assessed using American Academy of Neurology criteria, and interventions were categorized based on the likelihood of effectiveness. Clinical recommendations were then graded using the AAN guideline development framework.

A key shift in the 2025 update is the introduction of level A “must offer” and “must not offer” recommendations—categories that were absent in the earlier guideline. Intravenous prochlorperazine and greater occipital nerve blocks emerged as the only therapies with the highest level of supporting evidence and are now recommended as first-line parenteral options for eligible patients without contraindications. In contrast, intravenous hydromorphone received a level A “must not offer” designation due to consistent evidence showing poor efficacy and potential harm.

The guideline also reclassifies several commonly used treatments. Non-opioid options such as dexketoprofen, ketorolac, metoclopramide, and subcutaneous sumatriptan were upgraded to stronger recommendations, while intravenous paracetamol (acetaminophen) was downgraded and is no longer recommended for migraine-related pain relief in the ED.

Although newer agents such as the CGRP monoclonal antibody eptinezumab show promise, the authors caution that most supporting data come from outpatient settings. As a result, eptinezumab received a conditional recommendation limited to patients closely matching clinical trial populations, with no general ED-specific endorsement.

Key takeaways from the 2025 guideline update include: